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Axonal degeneration (AxD) following nerve injury, chemotherapy, and in several neurological disorders is an active process 
driven by SARM1, an injury-activated NADase. Axons of SARM1-null mice exhibit greatly delayed AxD after transection and 
in models of neurological disease, suggesting that inhibiting SARM1 is a promising strategy to reduce pathological AxD. 
Unfortunately, no drugs exist to target SARM1. We, therefore, developed SARM1 dominant-negatives that potently block 
AxD in cellular models of axotomy and neuropathy. To assess efficacy in vivo, we used adeno-associated virus–mediated 
expression of the most potent SARM1 dominant-negative and nerve transection as a model of severe AxD. While axons of 
vehicle-treated mice degenerate rapidly, axons of mice expressing SARM1 dominant-negative can remain intact for >10 d 
after transection, similar to the protection observed in SARM1-null mice. We thus developed a novel in vivo gene therapeutic 
to block pathological axon degeneration by inhibiting SARM1, an approach that may be applied clinically to treat manifold 
neurodegenerative diseases characterized by axon loss.
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Introduction
Axonal degeneration (AxD) is an early, potentially initiating 
event in prevalent neurological diseases including peripheral 
neuropathies, traumatic brain injury, Parkinson’s disease, and 
glaucoma (Howell et al., 2013; Johnson et al., 2013; Cashman 
and Höke, 2015; Tagliaferro and Burke, 2016). Although AxD is 
central to many neurological disorders, no treatments currently 
exist that effectively target axon breakdown.
Axon degeneration is a genetically encoded program of subcel-
lular self-destruction. Two large-scale forward genetic screens, 
one in invertebrates and one in mammals, independently identi-
fied a crucial role for sterile α and TIR (Toll-like interleukin 1 re-
ceptor) motif–containing protein 1 (SARM1) in this endogenous 
AxD program (Osterloh et al., 2012; Gerdts et al., 2013). Genetic 
deletion of SARM1 preserves Drosophila olfactory bulb distal 
axons for >50 d after a cut and mouse sciatic distal segments for 
>2 wk after transection. SARM1 is not only necessary for AxD 
but is also sufficient (Gerdts et al., 2015). Activation of SARM1 in 
healthy axons results in AxD, even in the absence of injury, thus 
indicating a fundamental role for SARM1 in the AxD program 
(Gerdts et al., 2016).
Genetic deletion of SARM1 protects axons from degeneration 
not only after a cut but also in models of several neurological 
diseases, including peripheral neuropathies (Geisler et al., 2016; 
Turkiew et al., 2017) and traumatic brain injury (Henninger et 
al., 2016; Ziogas and Koliatsos, 2018). This axon protection is as-
sociated with greatly improved functional outcomes, suggesting 
that targeting SARM1 is a viable strategy to treat neurological 
diseases characterized by early AxD. Importantly, SARM1 is ex-
pressed mainly in neurons, and SARM1 KO mice have a normal 
lifespan and no overt behavioral abnormalities, suggesting that 
targeting SARM1 may be well tolerated. Unfortunately, there are 
currently no known drugs that inhibit SARM1 activity.
SARM1 is a multidomain protein that consists of an autoin-
hibitory N terminus, tandem SAM domains that mediate con-
stitutive homomultimerization, and an executioner TIR NADase 
domain (Gerdts et al., 2013, 2016; Essuman et al., 2017). Upon 
injury, N-terminal inhibition is relieved, allowing for TIR–TIR 
interactions that activate the intrinsic NADase enzyme, thereby 
cleaving the essential metabolic cofactor NAD+ and driving AxD 
(Gerdts et al., 2016; Essuman et al., 2017). Because SARM1 exists 
as a homomultimer, coexpression of mutant SARM1 with wild-
type SARM1 can act as a dominant-negative, blocking wild-type 
SARM1 function (Gerdts et al., 2013). SARM1 lacking a TIR do-
main inhibits wild-type SARM1 function, likely by disrupting the 
TIR–TIR interactions that activate the enzyme. In addition, we 
previously identified a highly conserved residue in the TIR do-
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main that is required for the relief of N-terminal autoinhibition 
and, hence, injury-induced activation of SARM1 (Summers et 
al., 2016). Expression of this SARM1 mutant (SARM1-K597E) de-
lays AxD in vitro by inhibiting the function of wild-type SARM1. 
While expressing these SARM1 dominant-negative mutants in 
wild-type neurons does inhibit pathological AxD, neither blocks 
axon loss as effectively as the absence of SARM1.
Here we introduced point mutations into human SARM1 and 
expressed the constructs in wild-type neurons to identify SARM1 
dominant-negatives that potently inhibit SARM1 function. We 
found several SARM1 single mutants that strongly inhibit AxD in 
vitro. Combining the best two of these yields a dominant-negative 
that potently inhibits SARM1 enzymatic function and protects 
axons in cellular models of axotomy and neuropathy as robustly 
as SARM1 KO neurons. Using adeno-associated virus (AAV)–me-
diated expression of this optimized construct in adult wild-type 
mice and sciatic nerve cut as a model of severe AxD, we demon-
strate axon preservation similar to that observed in SARM1 KO 
mice. We thus provide a novel strategy to effectively and endur-
ingly inhibit SARM1 function in vivo. We anticipate that AAV-me-
diated expression of SARM1 dominant-negatives could be used 
therapeutically to block pathological AxD and improve functional 
outcomes in neuropathies and likely other diseases characterized 
by acute and chronic AxD. Unlike traditional gene therapy that 
seeks to treat a single, genetic disorder, gene therapy targeting 
SARM1 has the potential to treat a wide range of diseases charac-
terized by a shared pathological process—axon loss.
Results and discussion
Identification of SARM1 dominant-negative mutants 
that inhibit AxD
To develop potent SARM1 dominant-negatives, we introduced 
individual point mutations in highly conserved regions of the 
N-terminal and TIR domains (Fig.  1  A) and tested if lentivi-
rus-mediated expression of these constructs decreases AxD. All 
constructs were well expressed in cultured dorsal root ganglion 
(DRG) neurons (Fig. S1). Axons were severed, and cell bodies were 
removed to avoid axon regrowth into the injury site. With the aid 
of high-throughput automated imaging and an automated AxD 
index (Sasaki et al., 2009), we assessed fragmentation of distal 
axons over time. Fragmentation of axons begins ∼6 h after cut 
and is complete by 24 h (Fig. 1, B and C). Expression of the previ-
ously discovered dominant-negatives SARM1-K597E (Summers 
et al., 2016) and SARM1-deltaTIR (Gerdts et al., 2013) in wild-type 
DRG neurons delays AxD until 36 h after axotomy (Fig. 1, B and 
C). We recently identified glutamic acid E642 as the key catalytic 
residue within the active site of the TIR NADase (Essuman et 
al., 2017). To evaluate if blocking enzyme function would yield 
a potent dominant-negative, we expressed SARM1-E642A in 
wild-type neurons. Although SARM1-E642A is nonfunctional 
when expressed in SARM1-KO neurons (Essuman et al., 2017), 
when SARM1-E642A is expressed in wild-type neurons axon 
fragmentation proceeds with the same kinetics as in wild-type 
axons expressing enhanced GFP (EGFP) vector (Fig. 1 B). Hence, 
the SARM1-E642A mutant is nonfunctional but does not act as a 
dominant-negative, suggesting that it cannot disrupt TIR–TIR in-
teractions that allow for activation of the wild-type TIR NADase. 
In contrast, introducing a point mutation at another highly con-
served residue in the TIR domain, at position H685 (Fig. 1 A), re-
sults in a dominant-negative that potently protects axons for 72 h 
after axotomy (Fig. 1, B and C). Mutating H685 to either Y or A 
yields constructs whose dominant-negative efficacy is indistin-
guishable, suggesting that it is the loss of the H rather than the 
conversion to any particular amino acid that generates the domi-
nant-negative effect (Fig. S2 A). Therefore, this histidine is likely 
necessary for the TIR–TIR interaction involved in SARM1 activity. 
The strongest dominant-negative effect was observed when a ly-
sine at 193 in the N terminus was mutated (Fig. 1 A). This lysine 
is present within a highly conserved region of the N terminus 
that we hypothesized could be necessary for injury-induced ac-
tivation of SARM1. SARM1-K193R expression in wild-type DRGs 
potently protects axons for 72 h after axotomy (Fig. 1, B and C). As 
with H685, mutating K193 to either R or A generates constructs 
whose dominant-negative activity is indistinguishable, suggest-
ing that it is the loss of the lysine that blocks injury-induced ac-
tivation of SARM1 (Fig. S2 A).
As a second index of neuronal health, we examined the mi-
tochondrial potential in severed axons using the fluorescent mi-
tochondrial membrane indicator tetramethylrhodamine methyl 
ester (TMRM). Activation of SARM1 causes a drop in mitochon-
drial membrane potential (Summers et al., 2016), which is in-
dicated by loss of red fluorescence. In wild-type DRG neurons 
expressing EGFP vector or SARM1-E642A, TMRM fluorescence 
is no longer observed 24 h after axotomy (Fig. 1 C). In contrast, 
TMRM-positive mitochondria are preserved in wild-type DRGs 
expressing the SARM1 dominant-negative mutations and in 
SARM1-KO DRGs (Fig. 1 C), indicating the morphologically intact 
severed axons remain metabolically active.
To evaluate whether these SARM1 mutants have prodegenera-
tive function on their own, we expressed either wild-type SARM1 
or the SARM1 mutants (Fig. 1 A) in cultured SARM1-KO DRG neu-
rons and assessed AxD after axotomy. Axons of SARM1-KO neu-
rons are completely intact for at least 72 h after axotomy (Fig. 1, 
D and E), whereas reintroducing enzymatically active wild-type 
SARM1 promotes rapid AxD after severing (Fig. 1, D and E). In 
contrast, expression of the dominant-negative mutants and 
SARM1-E642A in SARM1-KO DRGs does not induce AxD for at 
least 72 h after transection (Fig. 1, D and E) demonstrating that 
the evaluated SARM1 mutants do not possess prodegenera-
tive capabilities.
Combining the SARM1-K193R and H685A mutations blocks 
wild-type SARM1 enzymatic activity and potently protects 
from AxD in cellular models of axotomy and neuropathy
Although expression of SARM1-K193R (Fig.  1, B and C) and 
SARM1-H685A (Fig. S2 A) strongly delays AxD after axotomy, the 
protection is less robust than deletion of SARM1 (Fig. 1, B and C). 
We therefore evaluated whether a SARM1 molecule with muta-
tions at both K193 and H685 would result in even more potent 
dominant-negative activity. We generated a construct with both 
mutations as well as a third mutation, H194A, and we call this 
construct the SARM1-compound dominant-negative (SARM1-
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does not impact the potency of SARM1-CDN (Fig. S2 B); however, 
since it was generated first and gave such a strong dominant-neg-
ative effect, the remainder of our analysis is with SARM1-CDN. 
Expression of SARM1-CDN completely prevents AxD (Fig. 2, A 
and B) and preserves TMRM-positive mitochondria (Fig. 2 C) for 
at least 96 h after axotomy. Upon activation, wild-type SARM1 
rapidly degrades NAD+ (Gerdts et al., 2015; Sasaki et al., 2016; 
Essuman et al., 2017), which results in local metabolic failure 
Figure 1. Identification of SARM1 dominant-negative transgenes. (A) Schematic representation of the domain structure of human SARM1. Individual 
point mutations are indicated by red triangles. Dotted segments indicate deleted regions. deltaTIR, aa 1–27 and 560–724 deleted; mt, mitochondrial binding 
sequence; ARM, HEAT/Armadillo motif; SAM, sterile α motif. (B) Axons of wild-type DRG neurons expressing the indicated constructs or axons of SARM1-KO 
DRG neurons expressing EGFP vector were transected and imaged using high-throughput automated imaging at indicated time points. AxD was quantified 
using a DI, which ranges from 0 (perfectly intact) to 1 (perfectly fragmented). Shown are means ± SE (SEM) of three independent experiments. Data were 
tested with a two-way ANO VA showing significant main effects of groups F(6,14) = 25.57; P < 0.0001; time, F(7,98) = 138, P < 0.0001; and interaction F(42, 
98) = 8.809; P < 0.0001; post hoc Dunnett’s multiple comparison test; ****, P = 0.0001; vector versus deltaTIR, **, P = 0.0013; *, P = 0.0122; vector versus 
K597E, **, P = 0.0015. (C) Top: Representative brightfield micrographs of wild-type axons expressing indicated constructs or SARM1-KO axons taken 24 h 
after transection. Bottom: The mitochondrial potential was monitored with red fluorescent TMRM in the same axons as shown in the row above. Upon loss of 
mitochondrial membrane potential, the red fluorescent signal disappears. (D) Axons of SARM1-KO neurons expressing either enzymatically active, wild-type 
SARM1 or indicated constructs were transected, and AxD was determined over time. Data are presented as mean ± SEM. Two-way ANO VA shows significant 
main effect of groups F(5,12) = 122.5, P < 0.0001; time (F4,48) = 124, P < 0.001, and interaction F(20,48) = 38.94, P < 0.0001; Dunnett’s multiple comparison; 
****, P = 0.0001; n = 3 independent experiments; four wells averaged per experiment. (E) Representative brightfield images of SARM1-KO axons expressing 
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(Gerdts et al., 2015; Yang et al., 2015) and subsequent AxD. To 
assess whether SARM1-CDN also blocks this molecular activity of 
SARM1, we measured axonal NAD+ levels in healthy and injured 
axons. As expected, 4 h after transection, NAD+ is largely depleted 
in wild-type neurons expressing a control vector (Fig. 2 D). In 
contrast, NAD+ is maintained in wild-type neurons expressing 
SARM1-CDN and in SARM1-KO neurons (Fig. 2 D). Hence, ex-
pression of SARM1-CDN in wild-type neurons potently blocks 
SARM1 enzymatic function and its prodegenerative activity.
The loss of SARM1 inhibits AxD in models of disease, includ-
ing traumatic brain injury (Henninger et al., 2016; Ziogas and 
Koliatsos, 2018) and chemotherapy-induced peripheral neu-
ropathy (Geisler et al., 2016; Turkiew et al., 2017). To examine 
the effects of SARM1-CDN in chemotherapy-induced peripheral 
neuropathy, we treated wild-type DRGs with vincristine and ob-
served complete fragmentation of axons 48 h after application 
of the drug (Fig. 2 E). In contrast, axons of both SARM1-KO neu-
rons as well as wild-type neurons expressing the SARM1 dom-
inant-negative mutant are morphologically intact and retain 
TMRM-positive mitochondria for at least 96 h after vincristine 
application (Fig. 2, E and F). Taken together, these data demon-
strate that expressing SARM1-CDN in wild-type neurons potently 
inhibits SARM1 function in response to diverse insults in vitro.
SARM1-CDN is strongly expressed in DRG neurons and 
peripheral nerves upon AAV-mediated gene transfer
We next tested if SARM1-CDN exhibits axoprotective proper-
ties in vivo. As a proof of concept, we used sciatic nerve tran-
section as a model of severe pathological AxD, reasoning that 
this is the most robust test of efficacy. SARM1-CDN fused to 
EGFP (Fig.  3 A) or EGFP alone were cloned into an AAV8 vec-
tor and expressed under the neuron-specific human synapsin 
(Syn) promoter (Fig. 3 A). 5 wk after intrathecal administration 
of AAV8-Syn-SARM1-CDN-EGFP (AAV-SARM1-CDN) or con-
Figure 2. SARM1-CDN potently inhibits wild-type SARM1 function. (A) Degeneration of wild-type DRG neurons expressing EGFP vector or the SARM1-CDN 
and of SARM1 KO neurons expressing EGFP vector after transection. DI ranges from 0 (completely intact) to 1 (completely fragmented). Data are presented as 
mean ± SEM, tested with a two-way ANO VA, which shows significant main effects of group F(2,9) = 2,710, P < 0.0001; time (F8,72) = 298.7, P < 0.0001, and 
interaction F(16,72) = 154, P < 0.0001. Dunnett’s multiple comparison test vector versus SARM1-CDN and SARM1-KO, ****, P = 0.0001. (B and C) Represen-
tative brightfield (B) and TMRM (C) images of axons expressing constructs indicated in A, at 96 h after axotomy. (D) HPLC was used to measure NAD+ levels in 
wild-type and SARM1-KO neurons expressing EGFP vector or SARM1-CDN from axon extracts 4 h after transection and normalized to baseline (immediately 
after cut). A one-way ANO VA shows a significant main effect F(2,6) = 20.01, P = 0.0022; post hoc Tukey’s multiple comparison test shows vector versus SARM1-
CDN, **, P = 0.0036; vector versus SARM1-KO, **, P = 0.0039; SARM1-KO versus SARM1-CDN, P = 0.9969. n = 3 independent experiments. (E) Wild-type DRG 
neurons expressing EGFP vector or SARM1-CDN and SARM1-KO neurons were treated with 40 nM vincristine or vehicle and AxD determined using the DI. 
Data are represented as means ± SEM; two-way ANO VA shows significant main effect of groups F(3,8) = 259.6; P < 0.0001; time F(5,40) = 89.28, P < 0.0001; 
and interaction F(15,40) = 38.59; P < 0.0001; post hoc Dunnett’s multiple comparison test shows wild-type vector vincristine versus SARM1-CDN vincristine, 
SARM1-KO vincristine, and SARM1-KO vehicle, ****, P = 0.0001; n = 3 independent experiments. (F) Representative brightfield (top row) and TMRM (bottom 
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trol EGFP virus (Fig. 3 B) we observed robust EGFP labeling of 
DRGs and peripheral nerves, including the sciatic (Fig. 3, C and 
E) and intercostal nerves (Fig. 3 C). DRGs are efficiently trans-
duced as determined by staining with the neuronal marker 
PGP9.5 (Fig. 3 D).
Before evaluating the role of the SARM1-CDN in blocking 
injury-induced AxD, we first assessed whether expression of 
AAV-SARM1-CDN induces morphological changes to axons in 
the absence of injury. Axons of sciatic nerves of mice injected 
with AAV-SARM1-CDN and AAV-EGFP appeared morphologically 
intact with no significant difference in axon size distribution and 
G ratio (Fig. S3). Hence, expression of SARM1-CDN has no detect-
able influence on axons in the absence of injury.
SARM1-CDN potently protects from AxD in vivo
5 d after sciatic transection, axons are largely absent in the distal 
nerve segment in mice injected with control virus, as evidenced 
by lack of EGFP fluorescence and loss of neurofilament and pe-
ripherin staining (Fig. 3 E). In contrast, EGFP fluorescence and 
neurofilament and peripherin staining are readily observed in 
nerves of mice injected with AAV-SARM1-CDN (Fig. 3 E), indicat-
ing that axons expressing the dominant-negative are protected 
from degeneration.
The severity of axonal loss after nerve cut and degree of 
protection afforded by the dominant-negative are even better 
appreciated using plastic-embedded thin sections. 5 d after tran-
section, signs of widespread Wallerian degeneration, including 
Schwann cells with myelin debris, lipid-laden histiocytes, and 
axon remnants with dark cytoplasm (Fig. 4, A, A′, C, and C′), are 
apparent in cross sections of the sural nerve, a sensory branch 
of the sciatic nerve distal to the cut. In contrast, in mice injected 
with AAV-SARM1-CDN, myelinated axons are remarkably well 
preserved, with normal shape, myelin thickness, and internal 
architecture (Fig. 4, B, B′, D, and D′). With the aid of electron mi-
croscopy, it becomes evident that this protection also extends to 
unmyelinated axons (Fig. 4, D and D′). When we compared num-
bers of myelinated axons on the injured and uninjured sides, 
mice injected with EGFP vector show a reduction of ∼99% (ipsi-
lateral 5 ± 0.9 axons/nerve; contralateral 446 ± 57 axons/nerve; 
n = 4 mice; Fig. 4 E), whereas there is no significant axon loss 
in mice expressing SARM1-CDN (cut site, 389 ± 13 axons/nerve; 
contralateral 396 ± 28 axons, n = 5 mice; Fig. 4 E) or in SARM1-KO 
mice (Fig. 4 E). Even 10 d after transection, distal axons are pres-
ent in mice injected with SARM1-CDN (Fig. 4 G). While we did 
not detect axons in the sural nerves of the vector treated group 
at that time point (0.3 ± 0.3 axons; n = 3 mice; Fig. 4, F and G), 
Figure 3. SARM1-CDN efficiently transduces DRGs in vivo and protects from AxD. (A) Top: Schematic of the AAV vector expressing human SARM1-CDN 
under control of the neuron-specific human synapsin promoter (Syn-SARM1-CDN-EGFP). Bottom: Schematic of the EGFP vector (Syn-EGFP) used for control 
experiments. WPRE, woodchuck hepatitis virus posttranscriptional regulatory element; ITR, inverted terminal repeats. (B) AAV8-Syn-SARM1-CDN-EGFP or 
EGFP vector (AAV8-Syn-EGFP) were injected intrathecally (i.t.) into mice at postnatal day 11 or 12 (P11/12). 5 wk later, the right sciatic nerve was transected, 
and 5 d later, tissue was collected for analysis. (C) Representative micrographs taken in situ of (from left to right) DRGs (asterisk) attached to the spinal cord 
(SC), the left (uninjured) sciatic nerve (arrow) with its branches (arrowheads), and intercostal nerves (white arrowhead) expressing GFP 5.5 wk after injection 
with AAV8-Syn-SARM1-CDN-EGFP; m, muscle. Bars, 2 mm. (D) Representative confocal image of a 6-µm-thick section of a DRG after injecting EGFP vector (left 
column; Syn-EGFP) or SARM1-CDN (right column; Syn-SARM1-DN-EGFP). Sections were stained with PGP9.5 (red; DRG neurons) and anti-GFP (green; construct 
expression) and coverslipped with Vectamount containing DAPI (blue; nuclear marker). (E) Representative confocal image of a 6-µm-thick section of the right 
(transected) sciatic nerve taken 5 d after cut in mice injected with the EGFP vector (left column; Syn-EGFP) or SARM1-CDN (right column; Syn-SARM1-CDN-
EGFP). Sections were stained with antibodies to Neurofilament 200 (NF) and peripherin (red; axonal markers) and green fluorescent protein (green; construct 
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we identified 160 ± 40 axons per sural nerve (n = 3 mice) in the 
AAV-SARM1-CDN group, which is ∼59 ± 15% of the number of 
axons present in the uninjured nerve (Fig. 4 F). This preservation 
is comparable to SARM1-KO mice (Fig. 4, F and G), in which 79 ± 
9% of axons remain distal to injury site (Fig. 4, F and G).
Concluding remarks
In this study, we establish AAV-mediated, neuron-specific ex-
pression of a SARM1 dominant-negative as a powerful tool to 
potently inhibit AxD in vivo. These findings demonstrate that 
SARM1 acts neuron-autonomously and show that it can be effec-
tively targeted in adult wild-type mice. Our findings translate the 
recent dramatic progress in defining the molecular mechanism 
of axon degeneration into a novel therapeutic strategy to block 
pathological AxD in neurological disorders.
SARM1 is a multimer, and mutant SARM1 coassembles with 
wild-type SARM1 (Gerdts et al., 2013). Hence, the relative dom-
inant-negative efficacy of distinct SARM1 mutants may give 
mechanistic clues to SARM1 function, although differences in 
expression and/or localization may also contribute. Mutating 
residues K193 or H685 in SARM1 generates very potent domi-
nant-negative transgenes, indicating that K193 in the N terminus 
and H685 in the TIR domain are likely essential for activation 
of SARM1. Interestingly, mutating the active site of the TIR 
domain (E642A) completely abrogates SARM1 function when 
reexpressed in SARM1 null neurons, but has no dominant-neg-
ative effect when expressed in wild-type neurons. This suggests 
that each enzymatic active site in the complex functions inde-
pendently. However, our data (Gerdts et al., 2013) as well as a vast 
literature on other TIR domain proteins (Narayanan and Park, 
2015) demonstrate that TIR dimer interactions are necessary for 
activation of TIR domains. We suggest that while the E642 resi-
due is necessary for intrinsic enzyme activity of a TIR domain, 
the H685 residue is necessary for activation of enzyme activity 
in the adjacent, interacting TIR domain, and so when mutated 
can act as a dominant-negative. In addition, N-terminal residues 
such as K193 appear to be required for injury-induced activation 
of SARM1 via relief of autoinhibitory interactions with the TIR 
domain. Because the effects of H685A and K193R mutations are 
additive, their mechanisms of inhibition are likely distinct.
Many common neurodegenerative diseases are character-
ized by early AxD (Burke and O’Malley, 2013; Howell et al., 2013; 
Figure 4. SARM1-CDN protects from AxD in vivo with efficacy similar to SARM1-KO. (A and B) Representative photomicrographs of toluidine blue–stained 
semithin cross sections of the right sural nerve 5 d after transection of the sciatic nerve in mice injected with vector (A; n = 4) or SARM1-CDN (B; n = 5). A′ and 
B′ show enlargements of areas indicated by rectangles in A and B. The arrow and arrowhead indicate lipid-laden histiocytes and myelin debris, respectively. (C 
and D) Representative electron micrographs of the right sural nerve of a mouse injected with EGFP vector showing complete loss of internal nerve architecture 
(C) whereas unmyelinated (asterisks) and myelinated axons are preserved after SARM1-CDN injection (D). C′ and D′ show enlargements of areas indicated by 
rectangles in C and D. (E and F) All axons in cross sections of the entire sural nerve were counted in wild-type mice injected with vector (n = 4 in E; n = 3 in F) or 
SARM1-CDN (n = 5 in E, n = 3 in F) or in SARM1-KO mice (n = 5 in E and F) and expressed as percentage of axon numbers of the respective intact contralateral 
sides at 5 (E) and 10 (F) d after transection. Data are presented as mean ± SE (SEM), tested with a one-way ANO VA, which shows significant main effects in E 
(F(2,11) = 97.13, P < 0.0001; post hoc Tukey’s multiple comparison test shows vector versus SARM1-SARM1-CDN, ****, P < 0.0001; vector versus SARM1-KO, 
****, P < 0.0001; SARM1-CDN versus SARM1-KO, P = 0.5953) and F (F(2,8) = 20.73; P = 0.0007; Tukey’s multiple comparison test shows vector versus SARM1-
CDN, **, P = 0.0077; vector versus SARM1-KO, ***, P = 0.0005; SARM1-CDN versus SARM1-KO, P = 0.2543). n.s., not significant. (G) Representative micrographs 
of toluidine blue–stained sections of the sural nerve 10 d after cut. Bottom row displays enlargements of indicated areas in the images above. Bars, 50 µm (A 
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Johnson et al., 2013; Yin et al., 2016). Peripheral neuropathies 
are the most common neurodegenerative diseases, affecting >20 
million people in the US alone. Many neuropathies are caused 
by degeneration of long axons, yet specific therapies to block 
this degeneration do not exist. Furthermore, in some of the 
most prevalent diseases of the central nervous system, such as 
Parkinson’s disease, traumatic brain injury, and glaucoma, AxD 
precedes neuronal degeneration (Tagliaferro and Burke, 2016; 
Caminiti et al., 2017; Fazio et al., 2018; O’Keeffe and Sullivan, 
2018). Studies using Wallerian degeneration slow (wlds) mice, 
which harbor a spontaneous mutation that delays AxD (Lunn et 
al., 1989), and SARM1-KO mice demonstrate that inhibiting the 
axon destruction program leads to greatly improved functional 
outcomes (Wang et al., 2001, 2002; Sajadi et al., 2004; Meyer zu 
Horste et al., 2011; Geisler et al., 2016; Henninger et al., 2016; 
Fernandes et al., 2018). The active component of WLDs fusion 
protein is NMN AT1 (Araki et al., 2004), which inhibits SARM1 
(Gilley et al., 2015; Sasaki et al., 2016). However, expression of 
WLDs is less effective than genetic deletion of SARM1 in protect-
ing axons of older mice and in preserving synapses (Conforti et 
al., 2014; Gilley et al., 2017), suggesting that directly targeting 
SARM1 will provide better inhibition of pathological AxD. Here 
we demonstrate that viral delivery of SARM1-CDN in mice in-
duces long-lasting axon protection following sciatic nerve tran-
section, the most rapid and aggressive trigger of AxD, providing 
a template for gene therapy treatments of slower axon loss in 
chronic neurodegenerative diseases.
AAV-mediated gene delivery has been safely used in patients 
in clinical trials and has shown promising results in neurologi-
cal diseases, e.g., spinal muscular atrophy (Mendell et al., 2017; 
Sumner and Crawford, 2018). AAV effectively transduces neu-
rons, is not pathogenic, and supports long-lasting expression 
after a single delivery (Hwu et al., 2012; Mittermeyer et al., 2012). 
Thus, AAV-mediated expression of SARM1-CDN, if proven safe in 
humans, may be useful for the treatment of chronic neurodegen-
erative diseases, such as hereditary and idiopathic neuropathies 
and Parkinson’s disease, as well as acquired neuropathies, such 
as chemotherapy-induced neuropathy. In treating chemothera-
py-induced neuropathy, it is tempting to speculate that a single 
injection of AAV-SARM1-CDN may be sufficient to provide axon 
protection for the duration of chemotherapy treatment.
Materials and methods
All procedures were performed in accordance with guidelines 
mandated in the National Institutes of Health Guide for the Care 
and Use of Laboratory Animals and approved by the Washington 
University School of Medicine in St. Louis Institutional Animal 
Care and Use Committee (protocols 20170030 and 20150043). This 
manuscript was prepared in adherence to the ARR IVE guidelines. 
Pregnant C57Bl/6NTac mice were purchased from Taconic and 
pregnant CD1 mice were purchased from Charles River. SARM1 KO 
mice were a gift from Marco Colonna (Department of Pathology 
and Immunology, Washington University School of Medicine in St. 
Louis, St. Louis, MO; Szretter et al., 2009) and bred in our colony. 
Male and female mice were used for all experiments. Chemicals 
were purchased from Sigma-Aldrich unless indicated otherwise.
DRG culture
DRGs were dissected from embryonic day 13.5 (E13.5) or E14.5 
CD-1 (Charles River) or from E13.5 SARM1 KO mouse embryos in 
Dulbecco’s modified Eagle’s medium. DRG neurons were dissoci-
ated in 0.05% trypsin-EDTA at 37°C, resuspended in Neurobasal 
media (Invitrogen) containing 2% B27 (Invitrogen), 50 ng/ml 
nerve growth factor (Harlan Laboratories), 1 µM 5-fluoro-2-de-
oxyuridine, and 1 µM uridine and plated in 48-well plates coated 
with poly-D-lysine and laminin. Concentrated lentivirus was 
added at 50-fold final dilution the following day (DIV1). All ex-
periments with direct comparisons were performed on the same 
plate to minimize variability.
Lentiviral constructs and infection
Mammalian expression constructs were derived from an FCIV 
lentiviral vector (Araki et al., 2004) containing a ubiquitin pro-
moter and Venus marker. Venus-tagged SARM1 fusion proteins 
were created by inserting SARM1 cDNA in frame with Venus with 
an Ala-Thr-Thr linker between the SARM1 C terminus and Venus. 
SARM1 mutant constructs were generated by the megaprime PCR 
method. The SARM1 deletion mutant lacking residues 2–27 and 
561–724 (deltaTIR) was subcloned into FCIV using the InFusion 
system. The control vector contained Venus or EGFP under con-
trol of the ubiquitin promoter (EGFP vector). Successful inser-
tions of clones were verified by sequencing. Lentiviral particles 
were produced by cotransfection of the lentiviral expression vec-
tor FCIV with lentiviral packaging plasmid psPAX2 and vesicu-
lar stomatitis virus glycoprotein into HEK293T cells as described 
previously (Araki et al., 2004). Lentiviral particles were collected 
48 h after transfection and concentrated with Lenti-X concen-
trator (Clontech) to a final concentration of 1–10 × 107 infectious 
particles/ml. Lentiviral expression of constructs was confirmed 
by positive fluorescence signal in the cell bodies and ranged from 
92.2 ± 7.6% (SARM1-delta TIR) to 98.8 ± 0.7% (SARM1- E642A; Fig. 
S1) infected DRGs.
Axotomy and vincristine
DRG neurons were cultured in 48-well microtiter plates with cell 
bodies sequestered to allow imaging of axons by automated mi-
croscopy. On DIV8, axons of DRGs were severed manually near 
the somae with a 3-mm-wide flat blade under microscopic guid-
ance. Cell bodies were removed to preclude axon regeneration. 
Vincristine (40 nM in DMSO) or vehicle (DMSO) was added on 
DIV8 and remained in the wells until the end of the experiment.
Imaging and quantification of AxD
15–20 brightfield images per well of live axons were acquired at 
indicated time points using an Operetta high-content imaging 
system (PerkinElmer) with a 20× objective. Axon degeneration 
was quantified based on axon morphology and reported as the 
“degeneration index” (DI) using an ImageJ-based script (Sasaki et 
al., 2009); DI ranges from 0 (perfectly intact) to 1 (perfectly frag-
mented). Values >0.5 indicate extensive axon degeneration. All 
images were inspected, and fields without axons or inadequate 
imaging were omitted. 10–15 images per well were measured as 
technical replicates. All experiments were performed at least 
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for each experiment. To assess mitochondrial potential, TMRM 
(Thermo Fisher Scientific) was added, and axons were imaged 
30 min later with an inverted Olympus CKX41 microscope and 
Nikon DS-QilMC camera. Exposure times were kept constant 
between constructs. Brightfield images were obtained in phase 
contrast using the same microscope and camera.
HPLC quantification of NAD+
CD1 E13.5 DRGs and SARM1 KO E13.5 DRGs were plated as spot 
cultures in 24-well plates coated with poly-D-lysine and lami-
nin. On DIV1, neurons were transduced with concentrated virus 
expressing either Ubiquitin-EGFP or Ubiquitin-SARM1-CDN- 
Venus. On DIV6, axons were severed, and cell bodies were re-
moved as described. Immediately (0 h time point) or 4 h after 
axotomy, axons were washed with cold 0.9% saline and lysed by 
addition of 0.5 M perchloric acid. Extracts were centrifuged, and 
supernatants were collected, neutralized with 3 M K2CO3, and di-
luted in potassium phosphate buffer. NAD+ was assayed by HPLC 
on an LC-18T HPLC column (Supelco) at a flow rate of 1 ml/min. 
Elution peaks were matched to NAD+ standards. Four wells per 
condition were averaged, and three independent experiments 
were performed.
AAV constructs and virus injections
AAV vector expressing EGFP under control of the human syn-
apsin promoter was obtained from Addgene (gift from Bryan 
Roth, School of Medicine at the University of North Carolina 
at Chapel Hill, NC; Addgene #50465) and used as EGFP vector 
control (Addgene viral prep #50465-AAV8). pAAV-hSyn-EGFP 
(Addgene #50465) was cut with BamHI and NcoI, and SARM1-
K193R/H194A/H685A (SARM1-CDN) was inserted between the 
synapsin promoter and EGFP sequence using inFusion (Clon-
tech) system. AAV8-hSYN-SARM1-CDN-EGFP was generated by 
the viral vector core of the Hope Center for Neurological Disor-
ders at Washington University in St. Louis. Viral particles were 
purified by iodixanol gradient ultracentrifugation, and virus 
titers were measured by dot blot. Under light anesthesia with 
Avertin, 6 × 1011 viral genomes were injected intrathecally at L6/
S1 into male (n = 7) and female (n = 10) C57Bl/6 mice (Taconic) 
at postnatal day 11 or 12. Two female mice injected with EGFP 
vector died subsequently, whereas none injected with the SARM1 
dominant-negative construct died.
Sciatic nerve transection and tissue collection
5 wk after virus injection, one group of mice (n = 9) was anesthe-
tized with isoflurane, the right sciatic nerve transected and nerve 
ends bent away from each other to prevent reconnection. 5 d after 
nerve transection, mice were anesthetized with Avertin and, 
after the sciatic and sural nerves were dissected out, perfused 
transcardially with 4% paraformaldehyde in phosphate buffered 
saline. Spinal cord and DRGs were dissected out, cryoprotected 
overnight in 30% sucrose, and frozen in Tissue-Tek optimal cut-
ting temperature compound (Electron Microscopy Sciences) in 
liquid 2-methylbutane cooled by dry ice. The sciatic nerves of 
a second group of mice (n = 6) were transected 8 wk after virus 
injection, and tissue was collected 10 d later as described above. 
For comparison, age-matched (11 wk) SARM1 KO mice (n = 10; 
5 male/5 female) received a sciatic nerve transection, and sci-
atic and sural nerves were dissected out 5 (n = 5 mice; 2 female/3 
male) or 10 (n = 5 mice, 3 female/2 male) d after transection.
Toluidine blue staining and axon quantification
Sural and sciatic nerves were fixed over night by immersion in 
freshly prepared 3% glutaraldehyde in 0.1 M PBS and processed 
as described recently (Geisler et al., 2016). Cross sections (400 
nm thick) were cut using a Leica EM UC7 ultramicrotome and 
stained with 1% toluidine blue (Fisher Scientific). Sural nerve 
sections were imaged with the 63× oil immersion objective of a 
Leica DMI 4000B microscope equipped with a Leica DFC 7000-T 
Camera. Micrographs were stitched using the Leica software, and 
all axons per cross section were counted in ImageJ. To determine 
axon size distribution and G ratios of the sciatic nerve, four non-
overlapping areas per cross section were imaged with a 100× oil 
objective of a Zeiss Axioskop and photographed with a Hitachi 
camera. Photographs were analyzed with a customized semiau-
tomated binary imaging analysis method (Hunter et al., 2007). 
Three nerves per treatment group were analyzed, and results of 
four areas per nerve were averaged. All analyses were done by 
blinded observers.
Electron microscopy
Selected blocks of sural nerves were used to cut 90-nm-thick ul-
trathin sections, which were stained with uranyl acetate and lead 
citrate and viewed with a JEOL JEM 1400 TEM.
Immunohistochemistry
6-μm-thick sections of DRGs and sciatic nerves were cut at the 
cryostat (Leica CM1860), mounted onto slides, and processed as 
described recently (Geisler et al., 2016). Experiments with direct 
comparisons between groups were performed in parallel to min-
imize variability. Primary antibodies included rabbit anti-Pro-
tein Gene Product 9.5 (1:1,000; EMD Millipore; #AB1761-1-I), 
rabbit anti-peripherin (1:250; EMD Millipore; #AB1530), rabbit 
anti-neurofilament 200 (1:1,000, Sigma-Aldrich; #N4142), and 
mouse-anti-GFP conjugated to Alexa Fluor 488 (1:250; Thermo 
Fisher Scientific; #A-21311). Secondary antibody was Alexa 
Fluor 594–conjugated goat anti-rabbit (Invitrogen) at a dilution 
of 1:500. Sections were coverslipped with Vectashield with DAPI 
(Vector Laboratories) to allow visualization of nuclei. Sciatic 
nerves and DRGs were imaged with the confocal mode of the 
Leica DMI 4000B using 40× and 20× immersion oil objectives, 
respectively. PGP9.5-positive and GFP-positive DRG neurons 
were counted in one stitched confocal slice of the entire DRG 
in ImageJ. One section each of two different DRGs was counted 
per animal, and values were averaged. GFP was expressed in 
85 ± 0.4% of PGP9.5-positive DRG neurons after injection of 
AAV8-Syn-SARM1-CDN-EGFP.
Statistical analysis
Unless otherwise stated, data are reported as means ± SEM. Be-
tween-group comparisons were made with one-way or two-way 
ANO VA as appropriate. Two-sided significance tests were used 
throughout, and P < 0.05 was considered statistically significant. 
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Fig. S1 depicts photomicrographs showing expression of SARM1 
dominant-negative–Venus constructs in DRG neurons and as-
sociated quantification confirming that all constructs are well 
expressed. Fig. S2 depicts graphs comparing different SARM1 
dominant-negative constructs demonstrating no difference in 
axon protection between SARM1-H685A and SARM1-H685Y and 
between SARM1-K193R and SARM1-K193A, as well as between 
SARM1-K193R/H685A and SARM1-K193R/H194A/H685A. Fig. 
S3 depicts representative photomicrographs of toluidine blue–
stained semithin cross sections of the sciatic nerve following 
injections of EGFP vector (AAV-Syn-EGFP) and the SARM1 dom-
inant-negative (AAV-Syn-SARM1-CDN-EGFP) and associated 
analysis of axon size distribution and G ratios, revealing no sig-
nificant difference between nerves from mice injected with EGFP 
vector and the SARM1 dominant-negative.
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